Platinum Equity to acquire Energy Distribution Partners after 45 acquisitions and threefold EBITDA growth
Senores Pharmaceuticals (SENORES) targets 3.2bn annual manufacturing units, yet 50% to 70% utilisation raises a bigger question
Aspen Neuroscience (ASPE) prices $140.6m IPO at $15 as Parkinson’s therapy enters pivotal development phase
Read More Pharma Industry News OSR Holdings (NASDAQ: OSRH) explores royalty-driven licensing for Vaximm’s cancer therapy Vaximm may license its oral cancer therapy VXM01 in a deal worth up to $815M. Find out how OSR Holdings plans to turn this into a royalty-driven biotech play. byPallavi MadhirajuNovember 23, 2025